Lv31
314 积分 2021-04-09 加入
The language of chromatin modification in human cancers
5小时前
已完结
Taking Me away: the function of phosphorylation on histone lysine demethylases
10天前
已完结
20 years of histone lysine demethylases: From discovery to the clinic and beyond
10天前
已完结
RNA sequencing: the teenage years
14天前
已完结
Integrated multiomic profiling of breast cancer in the Chinese population reveals patient stratification and therapeutic vulnerabilities
14天前
已完结
ctDNA dynamics and mechanisms of acquired resistance in patients treated with osimertinib with or without bevacizumab from the randomised phase II ETOP-BOOSTER trial
26天前
已完结
Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial
26天前
已完结
Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA
26天前
已完结
Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial
26天前
已完结
A clinical review on third and fourth generation EGFR tyrosine kinase inhibitors for the treatment of non-small cell lung cancer
1个月前
已完结
皖公网安备34019202002308
